Joel Beatty's Stock Ratings

Baird Analyst

Joel Beatty is an analyst at Baird. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

27.9%

Smart Score

72.2%

Overall Average Return Percentile

86th

Number of Ratings

62
Buy NowGet Alert
05/17/2024BMRNBuy Now
Biomarin Pharmaceutical
$77.05-6.55%$104 → $72DowngradeOutperform → NeutralGet Alert
05/15/2024CLDIBuy Now
Calidi Biotherapeutics
$0.25709.72%$4.5 → $2MaintainsOutperformGet Alert
05/09/2024ACADBuy Now
ACADIA Pharmaceuticals
$15.1584.82%$31 → $28MaintainsOutperformGet Alert
05/07/2024AXSMBuy Now
Axsome Therapeutics
$77.5844.37%$108 → $112MaintainsOutperformGet Alert
05/01/2024PRAXBuy Now
Praxis Precision Medicine
$45.01159.94% → $117Initiates → OutperformGet Alert
05/01/2024LBPHBuy Now
Longboard Pharmaceuticals
$20.8472.74% → $36Initiates → OutperformGet Alert
04/30/2024GERNBuy Now
Geron
$3.7121.29% → $4.5DowngradeOutperform → NeutralGet Alert
04/17/2024ITCIBuy Now
Intra-Cellular Therapies
$65.3257.69%$83 → $103MaintainsOutperformGet Alert
04/11/2024NRIXBuy Now
Nurix Therapeutics
$16.1954.42%$24 → $25MaintainsOutperformGet Alert
04/11/2024AMLXBuy Now
Amylyx Pharma
$1.8463.04%$4 → $3MaintainsNeutralGet Alert
03/21/2024CLDIBuy Now
Calidi Biotherapeutics
$0.251721.86%$9 → $4.5MaintainsOutperformGet Alert
03/19/2024LPTXBuy Now
Leap Therapeutics
$2.60246.14%$11 → $9MaintainsOutperformGet Alert
03/19/2024ALKSBuy Now
Alkermes
$24.3851.76% → $37Initiates → OutperformGet Alert
03/19/2024AXSMBuy Now
Axsome Therapeutics
$77.5839.21% → $108Initiates → OutperformGet Alert
03/12/2024ACADBuy Now
ACADIA Pharmaceuticals
$15.15104.62%$40 → $31MaintainsOutperformGet Alert
03/11/2024AMLXBuy Now
Amylyx Pharma
$1.84117.39%$37 → $4DowngradeOutperform → NeutralGet Alert
03/01/2024ARGXBuy Now
argenx
$361.5835.52%$505 → $490MaintainsOutperformGet Alert
02/26/2024COGTBuy Now
Cogent Biosciences
$7.802.56%$14 → $8DowngradeOutperform → NeutralGet Alert
01/30/2024RAREBuy Now
Ultragenyx Pharmaceutical
$40.6467.32%$57 → $68MaintainsOutperformGet Alert
01/30/2024BMRNBuy Now
Biomarin Pharmaceutical
$77.0534.98%$127 → $104MaintainsOutperformGet Alert
01/30/2024ELFBuy Now
e.l.f. Beauty
$153.8920.22% → $185Initiates → NeutralGet Alert
01/30/2024ACADBuy Now
ACADIA Pharmaceuticals
$15.15164.03% → $40Initiates → OutperformGet Alert
01/16/2024AMAMBuy Now
Ambrx Biopharma
—— → $28DowngradeOutperform → NeutralGet Alert
01/03/2024AMLXBuy Now
Amylyx Pharma
$1.841910.87% → $37Initiates → OutperformGet Alert
01/03/2024JAZZBuy Now
Jazz Pharmaceuticals
$108.6247.3% → $160Initiates → OutperformGet Alert
01/03/2024ITCIBuy Now
Intra-Cellular Therapies
$65.3227.07% → $83Initiates → OutperformGet Alert
10/09/2023CLDIBuy Now
Calidi Biotherapeutics
$0.253543.72% → $9Initiates → OutperformGet Alert
09/08/2023VAXXBuy Now
Vaxxinity
$0.097346.81% → $7Initiates → OutperformGet Alert
08/28/2023IMMPBuy Now
Immutep
$3.09126.54% → $7ReiteratesOutperform → OutperformGet Alert
08/15/2023LPTXBuy Now
Leap Therapeutics
$2.60669.2%$30 → $20MaintainsOutperformGet Alert

Recent Analyst Stock Rating News

Walmart To Rally Over 17%? Here Are 10 Top Analyst Forecasts For Friday
Critical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To Know
Key Takeaways From Nurix Therapeutics Analyst Ratings
Breaking Down argenx: 12 Analysts Share Their Views
Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
Analyst Ratings For Intra-Cellular Therapies
7 Analysts Assess Alkermes: What You Need To Know
ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings)
Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free